Tumor necrosis factor-α mediates hyperglycemia-augmented gut barrier dysfunction in endotoxemia

Critical Care Medicine

Volumn 37, Issue 3, 2009, Pages 1024-1030

  Yajima, Satoshi ^a   Morisaki, Hiroshi ^a   Serita, Ryohei ^a   Suzuki, Takeshi ^a   Katori, Nobuyuki ^a   Asahara, Takashi ^c   Nomoto, Koji ^c   Kobayashi, Fujio ^d   Ishizaka, Akitoshi ^b   Takeda, Junzo ^a  

^a KEIO UNIVERSITY   (Japan)

^b YAKULT CENTRAL INSTITUTE FOR MICROBIOLOGICAL RESEARCH   (Japan)

^c Research and Development Division   (Japan)

^d MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

Endotoxin; Gut mucosal permeability; Hyperglycemia; Insulin; TNF converting enzyme

Indexed keywords

CYTOKINE; DEXTRAN; GLUCOSE; INSULIN; ISOTHIOCYANIC ACID; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GROWTH; CONTROLLED STUDY; ENDOTOXEMIA; FLUORESCENCE; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; HYPERINSULINEMIA; INFLAMMATION; INSULIN BLOOD LEVEL; INTESTINE; MALE; MEMBRANE PERMEABILITY; MESENTERY LYMPH NODE; MICROFLORA; NONHUMAN; PRIORITY JOURNAL; RAT; STOMACH MUCOSA; WISTAR RAT; ANIMAL; BLOOD; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; PATHOPHYSIOLOGY; PERMEABILITY; PHYSIOLOGY;

ANIMALS; ENDOTOXEMIA; HYPERGLYCEMIA; INTESTINES; MALE; PERMEABILITY; RATS; RATS, WISTAR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 62849100004     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31819b53b6     Document Type: Article

References (40)

1. Marik PE, Raghavan M: Stress-hyperglycemia, insulin and immunomodulation in sepsis. Intensive Care Med 2004; 30:748-756
2. Krinsley JS: Association between hyperglycemia and increased hospital mortality in a heterogenous population of critically ill patients. Mayo Clin Proc 2003; 78:1471-1478
3. Van den Berghe G, Wousters P, Weekwers F, et al: Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345:1359-1367
4. Van den Berghe G, Wilmer A, Hermans G, et al: Intensive insulin therapy in the medical ICU. N Engl J Med 2006; 354:449-461
5. Brunkhorst FM, Engel C, Bloos F, et al: Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358:125-139
6. Ling PR, Smith RJ, Bistrian BR: Hyperglycemia enhances the cytokine production and oxidative responses to a low but not high dose of endotoxin in rats. Crit Care Med 2005; 33:1084-1089
7. Brix-Christensen V, Andersen SK, Andersen R, et al: Acute hyperinsulinemia restrains endotoxin-induced systemic inflammatory response: An experimental study in a porcine model. Anesthesiology 2004; 100:861-870
8. Van den Berghe G, Wousters P, Bouillon R, et al: Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control. Crit Care Med 2003; 31:359-366
9. Chen HI, Yeh DY, Liou HL, et al: Insulin attenuates endotoxin-induced acute lung injury in conscious rats. Crit Care Med 2006; 34:758-764
10. Meakins JL, Marshall JC: The gastrointestinal tract: The motor of multiple organ failure. Arch Surg 1986; 121:197-201
11. Kubes P: Nitric oxide modulates epithelial permeability in the feline small intestine. Am J Physiol 1992; 262:G1138-G1142
12. Suenaert P, Bulteel V, Lemmens L, et al: Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol 2002; 97:2000-2004
13. Esposito K, Nappo F, Marfella R, et al: Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: Role of oxidative stress. Circulation 2002; 106:2067-2072
14. Bengmark S: Use of some pre-and pro- and synbiotics in critically ill patients. Best Pract Res Clin Gastroenterol 2003; 17:833-848
15. Ellger B, Debaveye Y, Vanhorebeek I, et al: Survival benefits of intensive insulin therapy in critical illness: Impact of maintaining normo-glycemia versus glycemia-independent actions of insulin. Diabetes 2006; 55:1096-1105
16. Guo W, Magnotti L, Ding J, et al: Influence of gut microflora on mesenteric cytokine production in rats with hemorrhagic shock. J Trauma 2002; 52:1178-1185
17. Kosugi S, Morisaki H, Satoh T, et al: Epidural analgesia prevents endotoxin-induced gut mucosal injury in rabbits. Anesth Analg 2005; 101:265-272
18. Shimizu K, Ogura H, Asahara T, et al: Altered gut flora and environment in patients with severe SIRS. J Trauma 2006; 60:126-133
19. Jansen GJ, Wildeboer-Veloo AC, Tonk RH, et al: Development and validation of an automated, microscopy-based method for enumeration of groups of intestinal bacteria. J Microbiol Methods 1999; 37:215-221
20. Matsuda K, Tsuji H, Asahara T, et al: Sensitive quantitative detection of commensal bacteria by rRNA-targeted reverse transcription-PCR. Appl Environ Microbiol 2007; 73:32-39
21. Kikuchi H, Yajima T: Correlation between water-holding capacity of different types of cellulose in vitro and gastrointestinal retention time in vivo of rats. J SciFood Agr 1992; 60:139-146
22. Suzuki T, Morisaki H, Serita R, et al: Infusion of the β-adrenergic blocker esmolol attenuates myocardial dysfunction in septic rats. Crit Care Med 2005; 33:2294-2301
23. Finney S, Zekveld C, Elia A, et al: Glucose control and mortality in critically ill patients. JAMA 2003; 290:2041-2047
24. Condon C, Squires C, Squires L: Control of rRNA transcription in Escherichia coli. Microbiol Rev 1995; 59:623-645
25. Macfarlane S, Macfarlane G: Regulation of short-chain fatty acid production. Proc Nutr Soc 2003; 62:67-72
26. Blottiere B, Buechaer B, Galmiche J, et al: Molecular analyses of the effect of short-chain fatty acids on intestinal cell proliferation. Proc Nut Soc 2003; 62:101-106
27. Fallingborg J: Intraluminal pH of the human gastrointestinal tract. Dan Med Bull 1999; 46:183-196
28. Schneider SM, Le Gall P, Girard-Popau F, et al: Total artificial nutrition is associated with major changes in the fecal flora. Eur J Nutr 2000; 39:248-255
29. Xu DZ, Lu Q, Deitch EA: Nitric oxide impairs intestinal barrier function. Shock 2002; 17: 139-145
30. Lamarque D, Whittle BJ: Increase in gastric intramucosal hydrogen ion concentrations following endotoxin challenge in the rat and the actions of nitric oxide synthase inhibitors. Clin Exper Pharmacol Physiol 2001; 28:164-168
31. Gomez-Jimenez J, Salgado A, Mourelle M, et al: L-arginine: Nitric oxide pathway in endotoxemia and human septic shock. Crit Care Med 1995; 23:253-258
32. Ellger B, Langouche L, Richir M, et al: Modulation of regional nitric oxide metabolism: Blood glucose control or insulin? Intensive Care Med 2008; 34:1525-1533
33. Zolotarevsky Y, Hecht G, Koutsouris A, et al: A membrane-permeant peptide that inhibits MLC kinase restores barrier function in vitro models of intestinal disease. Gastroenterology 2002; 123:163-172
34. Ye D, Ma I, Ma TY: Molecular mechanism of tumor necrosis factor - A modulation of intestinal epithelial tight junction barrier. Am J Physiol 2006; 290:G496-G504
35. Mohler KM, Sleath PR, Fitzner JN, et al: Protection against a lethal dose of endotoxin by an inhibitor of tumor necrosis factor processing. Nature 1994; 370:218-220
36. Al-Sadi RM, Ma TY. IL-1β causes an increase in intestinal epithelial tight junction permeability. J Immunol 2007; 178:4641-4649
37. Lelkes E, Unsworth BR, Lelkes PI: Reactive oxygen species, apoptosis and altered NGF-induced signaling in PCI2 pheochromocytome cells cultured in elevated glucose: An in vitro cellular model for diabetic neuropathy. Neurotox Res 2001; 3:189-203
38. Kwoun MO, Ling PR, Lydon E, et al: Immunologic effects of acute hyperglycemia in nondiabetic rats. J Parenter Enteral Nutr 1997; 21:91-95
39. Tagesson C, Sjodahl R, Thoren B: Passage of molecules through the wall of the gastrointestinal tract I. A simple experimental model Scand J Gastroenterol 1978; 13:519- 524
40. Otamiri T, Sjödahl R, Tagesson C: Lysophosphatidylcholine potentiates the increase in mucosal permeability after small-intestinal ischaemia. Scand J Gastroenterol 1986; 21:1131-1136